{"version":"1.0","type":"link","title":"A glycoengineered anti-ROR1 antibody, GE-zilovertamab, selectively enhances antibody-dependent cellular cytotoxicity against chronic lymphocytic leukemia.","author_name":"Hasan MK 외","author_url":"https://prs-insight.online/author/Hasan%20MK","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/163166","thumbnail_width":1200,"thumbnail_height":630}